Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2ccPA in Symptomatic Knee Osteoarthritis
NCT04229394Phase 1Completed
- Sponsor
- Orient EuroPharma
- Start
- Feb 2018
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing 2ccPA with Placebo (2 arms). Primary endpoint: Adverse Events and Dose Limiting Toxicity at 85 days. Started Feb 2018; status: completed.
02
Drugs
2-carba-cyclic phosphatidic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04229394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229394.